News
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Creso Pharma on track to acquire ASX-listed Health House International, pro forma group has implied $33m in last quarter annualised sales.
Health & Biotech
Creso Pharma subsidiary Halucenex Life Sciences reports positive early results from Phase-2 trial
Health & Biotech
Creso’s Canadian cannabis subsidiary expands into 8th province
Health & Biotech
Could these Aussie psychedelics stocks carve a slice out of a ‘potential $63 billion’ global market?
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
News
In Case You Missed It: Cannabis comes out on top, with nickel and zinc not far behind
Health & Biotech
Creso Pharma’s Canadian subsidiary Mernova achieves cashflow positive position and delivers record revenues
News
Top 10 at 10: Cannabis dealers are making bank
Escrow Watch
ASX Escrow Watch: Lithium stocks including Pilbara Minerals ready to release shares in March
News
CLOSING BELL: ‘We may have gone too far’ says RBA boss poised to push things even further
News
CLOSING BELL: That sobbing you can hear is RBA chief Philip Lowe, because apparently we’re all big meanies
Health & Biotech
Creso Pharma subsidiary Halucenex Life Sciences eyes Aussie market entry following landmark TGA decision
Health & Biotech
ASX Health Stocks: Creso eyes psychedelic spinout off the back of landmark TGA decision
Health & Biotech
Australia just became the first country to recognise psychedelics as medicine. These are the ASX stocks you need to know about
Health & Biotech
Creso Pharma posts record of near $9 million of revenue in FY22 as its blazing M&A trail pays back
News
ASX Earnings Wrap: MoneyMe returns to profit, share price surges 30pc
Health & Biotech